Displaying my ignorance, but questions:1) Trial is targeting...

Displaying my ignorance, but questions:

1) Trial is targeting patients with 2nd & 3rd line disease status - does this mean they have previously been treated with other drugs at an earlier stage, and/or is it some measure of the stage of disease progression?

2) Trial patients are "irinotecan-naive" - does this mean they have not previously been treated with irinotecan, or does it mean something else?

3) Presumably, most trial patients are in Eastern Europe? Perhaps they have not previously been given the type of drug treatment now common in Western world? If so, could it mean that the control group (FOLFIRI, with irinotecan) might display longer PFS than a control group made up entirely of patients from the 'West'?